Lubrication of Direct-Compressible Blends with Magnesium Stearate Monohydrate and Dihydrate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Lubrication of Direct-Compressible Blends with Magnesium Stearate Monohydrate and Dihydrate
The influence of magnesium stearate (MgSt) on powder lubrication and finished solid-dose properties presents big challenges to drug manufacturers.


Pharmaceutical Technology


Experiment

Materials. Magnesium stearate, from vegetable source (monohydrate, lot no. J12404; and dihydrate, lot no. J04688), and acetaminophen, USP (APAP, lot no. 0048905C330) were provided by Mallinckrodt (St. Louis, MO) and used as received. Microcrystalline cellulose, NF (MCC, Avciel PH 101, 102, FMC Biopolymer, Philadelphia, PA); dibasic calcium phosphate, anhydrous (DCP, Encompress, JRS Pharma, Patterson, NY); and lactose monohydrate, spray-dried (LAC, Spectrum Chemicals, NJ) all were used as received. All materials were delumped before mixing.


Table I: Experimental design.
Methods. Diluent systems. Two ratios of binary diluents were used in the study (75:25 and 50:50) for each of MCC:DCP and MCC:LAC. These binary diluents constituted desirable solid dosage formulation systems in that the physical characteristics are unique. In the case of the MCC:DCP system, the physical interaction between a plastically deformable material (MCC) and an abrasively brittle material (DCP) with distinct particle–particle shapes was deemed informative. Moreover, using two grades of MCC with different particle sizes (Avicel PH 101 had a nominal mean particle size of 50 μm, and Avicel PH 102 had a nominal mean particle size of 100 μm) could present additional valuable information through their blending behavior. With respect to the MCC:LAC system, two plastically deformable diluents with distinct particle–particle morphology would be another opportunity to elucidate the influence of MgSt in such widely used pharmaceutical combinations (16).


Table II: Optimized design.
Experiment designs. APAP was used at concentrations of 1.25, 2.5, and 5.0% w/w. MgSt was used at concentrations of 0.3, 0.5, and 1.0% w/w. The experimental design was a modified Plackett–Burman fractional factorial having two levels with two center points. Eleven batches, each at 10-kg batch size, were blended in a 1-ft3 twin-shell blender (Patterson-Kelley, Stroudsburg, PA). This fractionalization allowed for a reduction of input variables or factors with the benefit of identifying the key factor variables that affected product quality. The design also enabled the evaluation of main effects aliased with two-way interactions (17). Tables I and II show the designs and independent variables (factors). Results from the experimental design provided information for optimization of the study (see Table I). Subsequently, six optimization batches were processed to substantiate the preliminary findings from the 11-batch runs (see Table II). The dependent variables (responses) included ejection force and total compression force (precompression and main compression forces).

Prelubrication blend uniformity was predicted using multiple effusivity sensors fitted to the blender as previously described (2, 12). Prelubrication and postlubrication blend uniformity samples were collected using a sampling thief (Globe Pharma, New Brunswick, NJ) for comparative analysis. Blend samples were analyzed for the APAP assay with an internally validated high-performance liquid chromatography (HPLC) method.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here